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Barrett’s Esophagus
Laura Hickey, BSN, RN, CNOR
Background
• Barrett’s Esophagus is a condition in which stratified 
squamous epithelial cells in the distal esophagus are 
replaced by metaplastic columnar epithelium 
with/without goblet cells (Clermont & Falk, 2018). 
• Cellular changes in the distal esophagus is a result of 
exposure to chronic reflux of acid and bile (Eluri & 
Shaheen, 2017).
• Barrett’s Esophagus is a precursor to esophageal 
adenocarcinoma.
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Pathogenesis
• The progressive multi-step cellular 
changes (metaplasia to dysplasia, to 
carcinoma) in the distal esophagus is 
from chronic reflux of acid and bile.
• The precise pathogenesis of Barrett’s 
Esophagus remains uncertain.
• The esophagus is lined with stratified 
squamous epithelial cells which are 
then replaced by metaplastic 
columnar epithelium.
• Not all patient’s with a diagnosis of 
Barrett’s Esophagus will progress to 
esophageal cancer.
• Those diagnosed with esophageal 
cancer may not have a history of 
esophageal dysplasia. 
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The incidence of esophageal adenocarcinoma, a deadly cancer, 
is escalating in comparison to other cancers (colon, lung, and 
breast) (Patel & Gyawali, 2019).  While providing surgical care 
for patients undergoing a transthoracic esophagectomy on a 
routine basis, there were significant trends amongst the patient 
population: history of gastroesophageal reflux disease, Barrett’s 
Esophagus diagnosis, patient demographics and social history. 
As a nurse providing care for patients with advanced disease, 
requiring invasive surgery, it was very appealing to understand 
the disease process and management of Barrett’s Esophagus.  
The exact pathogenesis of Barrett’s Esophagus to esophageal 
cancer remains uncertain, and there are limited strategies for 
early detection and prevention of esophageal cancer.  It is with 
sincere appreciation to care for this patient population and 
sincere determination to educate about the risks associated 
with Barrett’s Esophagus. 
Introduction
Who is at risk?
• Increased age (over 50), Caucasian males, with central 
obesity, and an underlying history of smoking, and/or 
chronic gastroesophageal reflux disease (GERD) (Eluri & 
Shahen, 2017; Patel & Gyawali, 2019). 
• GERD can be present with or without heartburn or with 
atypical symptoms such as: chest pain, cough, sore throat, 
and laryngitis. What’s more, symptoms diminish or 
“improve” as the disease develops (Patel & Gyawali, 2019). 
Diagnosis & Screening
• Diagnosing and screening for Barrett’s is challenging and 
complex.  The preferred screening method for those with 
associated risk factors for mucosal changes and dysplasia is 
an upper endoscopy by a gastroenterologist.  An upper 
endoscopy is preferred, as they are surveying tissue at the 
distal esophagus (Patel & Gyawali, 2019). 
• Gastroenterologists utilize the Prague Classification system 
to standardize mucosal changes in suspected tissue and are 
required to provide precise tissue sampling. 
• Endoscopic recognition of anatomical landmarks can be 
very challenging to identify due to esophagitis, respiration 
and peristalsis. (Clermont & Falk, 2018).
• Tissue sampling is reviewed and confirmed by two 
pathologists for diagnosis of Barrett’s Esophagus, low-grade 
dysplasia and high-grade dysplasia (Clermont & Falk, 
2018). 
Significance of Pathophysiology
• Researchers know that the epithelium in the distal esophagus changes, but 
the original cause of metaplasia and the process in which cells transform to 
cancer remain unknown. For example, acid reflux contributes to the 
pathogenesis of Barrett’s, the question remains, does acid reflux cause a 
chemical injury to the cells, or do the cells alter due to repeated 
inflammation?  
• A patient can be diagnosed with esophageal cancer without any history of 
Barrett’s Esophagus. What’s more, a patient with Barrett’s can still progress 
to esophageal cancer despite having no history of dysplasia (Eluri & 
Shaheen, 2017). 
• The uncertainty of disease pathogenesis contributes to difficulty identifying 
which patients to screen for disease. Not only does the deficit in 
understanding pathogenesis contribute to understanding those at risk for 
Barrett’s, it also makes it difficult to predict which patients will progress to 
cancer (Inadomi et al., 2018). 
• The use of biomarkers and other 
screening measures may improve the 
cost-effectiveness of Barrett’s 
esophagus screening, but are currently 
being developed with limited data 
(Patel & Gyawali, 2019). 
• The extent of tissue changes and 
dysplasia drive surveillance and 
treatment.
Diagnosis & Screening cont’d: 
• Identify and educate those at risk: Caucasian males, over 50 years of age, 
with central obesity, GERD, familial and tobacco use history. 
• Provide resources and education for dietary changes and smoking 
cessation. 
• Manage GERD symptoms with a once-daily dose of a proton pump 
inhibitor (Eluri & Shaheen, 2017).
• Know that nonsteroidal anti-inflammatory drugs (NSAIDs), for those 
with Barrett’s Esophagus, reduce progression of esophageal 
adenocarcinoma by 30% (Eluri & Shaheen, 2017). Keep in mind the 
bleeding risk with NSAIDs; does the benefit outweigh the risk?
• Screening is important, but is not cost effective to screen those that 
aren’t at risk.  Consider an upper GI study during routine colonoscopies 
for at-risk patients.  
• Consult and refer patients to a gastroenterologist to help guide and 
manage the disease. 
Implications for Nursing Care
Conclusion
Barrett’s Esophagus occurs in about 15% of those with GERD, 
and not all cases of Barrett’s progress to esophageal carcinoma 
(Eluri & Shaheen, 2017).  The overall goal is to identify those at 
risk to optimize screening and surveillance, because the 
prevalence of esophageal carcinoma is rising.   Barrett’s is 
complex to diagnose and screen, but there are multiple 
treatment modalities available. Identifying those at risk and 
minimizing acid reflux are the beginning stages of prevention.  
Current research is focused on the pathogenesis of Barrett’s, 
surveillance methods, and eradication therapies.  It is with 
great hope that further research will promote screening in at-
risk patient populations, similarly to other prevalent cancers 
like breast, colon and lung. 
